Want to see FR:IPN full AI Analyst Report?
Top Page
Ipsen
(IPN)
Select Model
Select Model
Rating:65Neutral
Price Target:
€157.00
▼(-5.42% Downside)
Action:Reiterated
Date:08/06/26
The score is primarily supported by solid underlying financial performance (steady revenue growth, healthy margins, and manageable leverage), but is held back by margin compression and cash-flow volatility. Technicals add caution due to negative MACD and a largely trendless setup around key moving averages, while valuation is restrained by a ~27 P/E and sub-1% dividend yield.
Positive Factors
Sustained Revenue Growth
Steady multi-year revenue expansion indicates sustained demand for Ipsen’s specialty medicines and growing commercial reach. Continued top-line growth can support investment in clinical development, lifecycle management, and commercial capabilities across oncology, rare diseases, and neuroscience.
Negative Factors
Margin Compression
The substantial decline in net margin shows that revenue growth has not translated into stable profitability at prior levels. If higher costs or unfavorable product mix persist, Ipsen may have less earnings available for research, commercial investment, and shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Steady multi-year revenue expansion indicates sustained demand for Ipsen’s specialty medicines and growing commercial reach. Continued top-line growth can support investment in clinical development, lifecycle management, and commercial capabilities across oncology, rare diseases, and neuroscience.
Read all positive factors
Ipsen (IPN) vs. iShares MSCI France ETF (EWQ)
Market Cap
€12.89B
Dividend Yield1.03%
Average Volume (3M)122.44K
Price to Earnings (P/E)25.1
Beta (1Y)0.62
Revenue Growth13.63%
EPS Growth14.45%
CountryFR
Employees5,535
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)6.20
Shares Outstanding83,814,530
10 Day Avg. Volume136,225
30 Day Avg. Volume122,445
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€170.00Price Target Upside2.41% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)14.34
Revenue Forecast (FY)€4.54B
Ipsen Business Overview & Revenue Model
Company Description
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; ...
How the Company Makes Money
Ipsen primarily makes money by selling prescription pharmaceuticals through its specialty medicine portfolio. Revenue is generated from net product sales (gross sales minus rebates, discounts, returns, and other allowances) to wholesalers, hospita...
Ipsen Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
78
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.05B | 3.68B | 3.57B | 3.31B | 3.16B | 2.75B |
| Gross Profit | 2.73B | 2.59B | 2.96B | 2.74B | 2.63B | 2.31B |
| EBITDA | 1.94B | 1.10B | 1.16B | 1.16B | 1.15B | 1.06B |
| Net Income | 512.60M | 444.50M | 345.90M | 644.40M | 648.60M | 646.60M |
Balance Sheet | ||||||
| Total Assets | 7.46B | 6.94B | 6.44B | 6.32B | 5.61B | 4.99B |
| Cash, Cash Equivalents and Short-Term Investments | 1.97B | 1.53B | 679.20M | 528.40M | 1.17B | 814.70M |
| Total Debt | 963.20M | 867.10M | 426.80M | 462.90M | 771.60M | 786.60M |
| Total Liabilities | 2.75B | 2.60B | 2.26B | 2.50B | 2.27B | 2.25B |
| Stockholders Equity | 4.71B | 4.34B | 4.18B | 3.83B | 3.34B | 2.74B |
Cash Flow | ||||||
| Free Cash Flow | 1.23B | 1.03B | 133.00M | 749.70M | 700.30M | 453.90M |
| Operating Cash Flow | 1.30B | 1.14B | 915.50M | 865.90M | 953.20M | 871.80M |
| Investing Cash Flow | -557.50M | -615.20M | -676.60M | -1.07B | -458.60M | -332.00M |
| Financing Cash Flow | -227.70M | 298.40M | -100.00M | -458.40M | -146.00M | -400.30M |
Ipsen Technical Analysis
Positive
166.00
Price Trends
153.42
Negative
157.33
Negative
155.68
Negative
Market Momentum
0.52
Negative
58.25
Neutral
69.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:IPN, the sentiment is Positive. The current price of 166 is above the 20-day moving average (MA) of 146.66, above the 50-day MA of 153.42, and above the 200-day MA of 155.68, indicating a neutral trend. The MACD of 0.52 indicates Negative momentum. The RSI at 58.25 is Neutral, neither overbought nor oversold. The STOCH value of 69.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:IPN.
Ipsen Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | €12.89B | 25.13 | 11.33% | 1.03% | 13.63% | 14.45% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | €486.67M | -2.84 | -152.15% | ― | -27.19% | -117.39% | |
46 Neutral | €1.54B | -27.56 | 89.71% | ― | ― | ― | |
44 Neutral | €7.10B | -17.22 | -85.88% | ― | ― | ― | |
43 Neutral | €572.08M | -3.39 | -121.83% | ― | ― | 45.11% | |
41 Neutral | €52.90M | -6.81 | 27.28% | ― | 12.66% | 44.01% |
* General Sector Average
FR:IPN
Ipsen
155.80
34.79
28.74%
FR:ABVX
Abivax SA
81.10
-9.40
-10.39%
FR:DBV
DBV Technologies
1.82
-0.70
-27.92%
FR:NANO
Nanobiotix
30.32
13.96
85.33%
FR:VLA
Valneva
2.56
-1.43
-35.92%
FR:AB
AB Science SA
0.55
-0.61
-52.84%
Ipsen Corporate Events
Ipsen Reports September 2026 Share Capital and Voting Rights
Oct 7, 2026
Ipsen is a French biopharmaceutical company listed on Euronext Paris, focusing on specialty care medicines in areas such as oncology, neuroscience, and rare diseases. Its shares trade under ISIN code FR0010259150, and the company is subject to Fre...
Ipsen reports €147 average price in latest share buyback transactions
Sep 28, 2026
Ipsen disclosed aggregate daily transactions in its own shares conducted on 21 and 22 September 2026 across several European trading platforms, including Euronext Paris and alternative venues. The company repurchased a total of 46,805 shares at a ...
Ipsen Repurchases 25,000 Shares Under Ongoing Buyback Programme
Sep 22, 2026
Ipsen disclosed details of its share buyback activity for the period from 14 to 18 September 2026, reporting no repurchases on the first three days and a total of 25,000 shares purchased on 17 and 18 September across several European trading venue...
Ipsen Adds Veteran Life Sciences Executive Mariette Finet to Its Board
Sep 18, 2026
Ipsen has co-opted Mariette Finet to its Board of Directors, replacing Michèle Ollier, who resigned in August 2026, and has named her to the Product Portfolio Committee. Her ratification will be submitted to the next shareholders’ meeti...
Ipsen Reports Share Buybacks for Late August and Early September 2026
Sep 15, 2026
Ipsen disclosed details of share repurchases carried out between 31 August and 4 September 2026 under the framework of Article 5 of the EU Market Abuse Regulation. The company bought a total of 11,270 of its own shares across Euronext Paris and th...
Ipsen Reports Weekly Share Buy-Back Activity on European Markets
Sep 14, 2026
Ipsen disclosed that it repurchased a total of 35,759 of its own shares during the week of 7 to 11 September 2026 under its ongoing buy-back programme. The transactions were executed mainly on Euronext Paris, with additional volumes on alternative...
Ipsen Buys Back 11,270 Shares in Early September Capital Management Move
Sep 7, 2026
Ipsen repurchased a total of 11,270 shares during the week of 31 August to 4 September 2026 under its ongoing share buy-back programme, at a daily weighted average price of approximately €162.82. Most of the repurchases occurred on 31 August...
Ipsen Updates Market on Share Capital and Voting Rights for August 2026
Sep 3, 2026
Ipsen reported that as of 31 August 2026, its share capital comprised 83,814,526 shares listed on Euronext Paris. The company detailed that its gross voting rights totaled 132,077,444, while net voting rights stood at 130,818,157 after excluding s...
Ipsen Reports Modest Share Buybacks in Late August 2026
Aug 31, 2026
Ipsen disclosed a weekly report on share repurchases conducted between 24 August and 28 August 2026 under its buy-back programme. During this period, the company repurchased a total of 3,645 shares on Euronext Paris (MIC code XPAR) at a daily weig...
Ipsen Reports No Share Buybacks in Week of 17–21 August 2026
Aug 24, 2026
Ipsen disclosed its weekly share repurchase activity for the period from 17 to 21 August 2026 under its existing buy-back programme. The report, published in line with market abuse regulation requirements, lists daily transactions but shows no ava...
Ipsen boosts hematology pipeline with Kartos Therapeutics acquisition
Aug 21, 2026
Ipsen has completed the acquisition of Kartos Therapeutics, adding navtemadlin, an oral MDM2 inhibitor in phase III development for myelofibrosis, to its oncology portfolio. The deal strengthens Ipsen’s late-stage hematology pipeline by targ...
Ipsen updates investors on July 2026 share capital and voting rights
Aug 20, 2026
Ipsen reported that as of 31 July 2026 its share capital is composed of 83,814,526 shares, reflecting the current equity base available to investors on Euronext Paris. The company disclosed a gross total of 132,132,996 voting rights and a net tota...
Ipsen Executes €156-Averaged Share Buyback Across European Markets
Aug 17, 2026
Ipsen disclosed that it repurchased a total of 10,000 of its own shares on 11 August 2026 across multiple trading venues, including Euronext Paris and alternative European platforms. The transactions were executed at a daily volume-weighted averag...
Ipsen Buys Back 17,818 Shares in Early August Under MAR Rules
Aug 10, 2026
Ipsen disclosed that it repurchased a total of 17,818 of its own shares between 4 and 5 August 2026 under the conditions of Article 5 of the EU Market Abuse Regulation. The transactions, executed primarily on Euronext Paris with additional trades ...
Ipsen Reports Share Buybacks on Euronext Paris in Late July 2026
Aug 3, 2026
Ipsen disclosed that it conducted share buyback transactions between 27 July and 31 July 2026 under Article 5 of the Market Abuse Regulation, purchasing a total of 12,313 shares on Euronext Paris. The transactions were executed at a daily weighted...
Ipsen lifts 2026 guidance on strong H1 results and pipeline-boosting deals
Jul 30, 2026
Ipsen reported strong first-half 2026 results, with total sales rising 23.5% at constant exchange rates to €2.19bn and core operating income climbing 28.8% to €845m, lifting the core operating margin to 38.6%. Earnings and free cash fl...
Ipsen Strengthens Board with Appointment of Governance Expert Catherine Bradley
Jul 29, 2026
Ipsen has appointed Catherine Bradley as an independent director to its Board, succeeding Ms Witts following the May 2026 shareholders’ meeting. Bradley brings more than three decades of investment banking and international markets experienc...
Ipsen Reports Share Buybacks Totaling 13,930 Shares Over Late July
Jul 27, 2026
Ipsen disclosed aggregated data on transactions in its own shares carried out between 20 and 24 July 2026 on European markets. Over the period, the company repurchased a total of 13,930 shares of its FR0010259150 stock at a daily weighted average ...
Ipsen’s Bylvay misses Phase III goal in biliary atresia, limiting expansion bid
Jul 24, 2026
Ipsen reported that its Phase III BOLD trial of Bylvay (odevixibat) in infants with biliary atresia who had undergone Kasai surgery failed to improve native liver survival versus placebo, underscoring the difficulty of treating this rare paediatri...
Ipsen Corrects June 2026 Voting Rights and Share Capital Disclosure
Jul 22, 2026
Ipsen has issued a corrective statement regarding its monthly disclosure of total shares and voting rights as of 30 June 2026, filed under French market regulations and in line with AMF requirements for Euronext Paris issuers. The company confirms...
Ipsen buys Memo Therapeutics to add first-in-class BK virus antibody
Jul 22, 2026
Ipsen has completed the acquisition of Memo Therapeutics AG, gaining control of potravitug, a first-in-class monoclonal antibody targeting BK polyomavirus reactivation in kidney transplant patients. The drug has shown significant antiviral activit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.